PCSK9: From Biology to Therapy
Gilles Lambert, Jean-Claude Tardif and Nabil Seidah
Video navigation menu
- ‘The biology of PCSK9 in humans: Just LDL-cholesterol or more?’ by Gilles Lambert 0:24
- ‘Genetic variation at the PCSK9 locus: A contributor to CV risk?’ by Jean-Claude Tardif 2:19
- ‘The PCSK9 protein: A key modulator of cardiovascular outcome’ by Nabil Seidah 4:22
- Lp(a) changes upon PCSK9 inhibition 6:30
- Theoretical safety issues with PCSK9 inhibition 7:55
- Clinical observations on safety of PCSK9 inhibition 10:22
Tomorrow's specialists meet today's experts | Tijdens ISA2015 zijn in de PACE-studio gesprekken opgenomen, waarin Nederlandse arts-onderzoekers internationale experts interviewden over hun expertise.
ZIe ook www.pace-cme.org.
Nabil Seidah discovered the PCSK9 protein. He discusses the advances in the field since its discovery in 2002 with Gilles Lambert, who studies the biological function of PCSK9 and Jean-Claude Tardif, who presented what human genetics can tell us about the potential benefit of PCSK9-inhibiting therapy.
They share their experience with Nick van Es (AMC Amsterdam, The Netherlands) and Lotte Koopal (UMC Utrecht, The Netherlands).
- The biology of PCSK9 in humans: Just LDL-cholesterol or more?
- Genetic variation at the PCSK9 locus: A contributor to CV risk?
- The PCSK9 protein: A key modulator of cardiovascular outcome
- Gilles Lambert (University of Nantes Medical School, Nantes, France)
- Jean-Claude Tardif (Canadian Institutes of Health Research, Montréal, Canada)
- Nabil Seidah (Laboratory of Biochemical Neuroendocrinology, Montréal, Canada)